Advertisement
Canada markets closed

  • S&P/TSX

    22,308.93
    -66.90 (-0.30%)
     

  • S&P 500

    5,222.68
    +8.60 (+0.16%)
     

  • DOW

    39,512.84
    +125.08 (+0.32%)
     

  • CAD/USD

    0.7317
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    78.20
    -1.06 (-1.34%)
     

  • Bitcoin CAD

    83,306.69
    -2,719.97 (-3.16%)
     

  • CMC Crypto 200

    1,260.01
    -98.00 (-7.22%)
     

  • GOLD FUTURES

    2,366.90
    +26.60 (+1.14%)
     

  • RUSSELL 2000

    2,059.78
    -13.85 (-0.67%)
     

  • 10-Yr Bond

    4.5040
    +0.0550 (+1.24%)
     

  • NASDAQ

    16,340.87
    -5.40 (-0.03%)
     

  • VOLATILITY

    12.55
    -0.14 (-1.10%)
     

  • FTSE

    8,433.76
    +52.41 (+0.63%)
     

  • NIKKEI 225

    38,229.11
    +155.13 (+0.41%)
     

  • CAD/EUR

    0.6789
    +0.0011 (+0.16%)
     
MARKETS LIVE BLOG:

STOCKS CLIMB AS DOW POSTS 8TH STRAIGHT WIN

Fed's Michelle Bowman echoes higher-for-longer mantra for interest rates

Ligand's Captisol Deals Set to Drive Growth in the Long Run

Zacks Equity Research
Updated
Crown Castle (CCI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

On Sep 26, 2017, we issued an updated report on Ligand Pharmaceuticals Incorporated LGND.

Ligand’s leading Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG NVS, Merck & Co., Inc. MRK and Amgen Inc. AMGN, thus in turn providing it with funds in the form of milestone and royalty payments.

Ligand receives royalties and milestone payments for several FDA-approved products that use its Captisol technology. Ligand’s major royalty revenues comes from sales of two key partnered assets — Novartis’ Kyprolis and Amgen’s Promacta. other latest product approvals include Spectrum’s Evomela, Lundbeck’s Carnexiv and Melinta Therapeutics’ Baxdela. Apart from these, several candidates are in late-stage development and expected to bring in royalties to the company once commercialized.

Regarding the company’s internal pipeline, various candidates are under observation and development for indications like diabetes. One such extremely advanced candidate is LGD-6972, presently undergoing a phase II study for treating type II diabetes. This month, the company reported positive top-line results from the study. It further expects LGD-6972 to bring in future licensing opportunities.

ADVERTISEMENT

Nonetheless, Ligand’s entry into the Medical Devices Segment with acquisition of multiple programs owned by CorMatrix is also encouraging.

However, Ligand obtains Captisol from a single supplier, Hovione — a major global supplier of active pharmaceutical ingredients and drug product intermediates, located in Portugal. Any interruption in Captisol’s supply would hit the company’s results.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.

It's not the one you think.

See This Ticker Free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Novartis AG (NVS) : Free Stock Analysis Report
 
Merck & Company, Inc. (MRK) : Free Stock Analysis Report
 
Amgen Inc. (AMGN) : Free Stock Analysis Report
 
Ligand Pharmaceuticals Incorporated (LGND) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research